The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment

Bone

Volumn 39, Issue 2, 2006, Pages 244-252

  Oxlund, H ^a   Ortoft G ^a   Thomsen, J S ^a   Danielsen, C C ^a   Ejersted, C ^a   Andreassen, T T ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Bone biomechanics; Bone formation; Bone resorption; Glucocorticoid; PTH

Indexed keywords

FLUOROCHROME; GLUCOCORTICOID; METHYLPREDNISOLONE; OSTEOCALCIN; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; BIOMECHANICS; BONE METABOLISM; BONE REMODELING; BONE TISSUE; CANCELLOUS BONE; COMPRESSIVE STRENGTH; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FLUORESCENCE MICROSCOPE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PERIOSTEUM; RAT; TIBIA; TRABECULAR BONE;

ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BONE AND BONES; BONE REMODELING; BONE RESORPTION; COMPRESSIVE STRENGTH; DIAPHYSES; FEMALE; FEMUR NECK; GLUCOCORTICOIDS; METHYLPREDNISOLONE; OSTEOCALCIN; OSTEOGENESIS; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PLIABILITY; RANDOM ALLOCATION; RATS; RATS, WISTAR; STRESS, MECHANICAL; TIBIA; TIME FACTORS;

EID: 33744917514     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.01.142     Document Type: Article

References (36)

1. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., and Arnaud C.D. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J. Bone Miner. Res. 15 (2000) 944-951
2. Canalis E., Bilezikian J.P., Angeli A., and Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 34 (2004) 593-598
3. Hodsman A.B., Kisiel M., Adachi J.D., Fraher L.J., and Watson P.H. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH (1-34) therapy in women with severe osteoporosis. Bone 27 (2000) 311-318
4. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
5. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18 (2003) 9-17
6. Lindsay R., Scheele W.H., Neer R., Pohl G., Adami S., Mautalen C., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164 (2004) 2024-2030
7. Rehman Q., Lang T.F., Arnaud C.D., Modin G.W., and Lane N.E. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int. 14 (2003) 77-81
8. Lane N.E., Sanchez S., Modin G.W., Genant H.K., Pierini E., and Arnaud C.D. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102 (1998) 1627-1633
9. Ørtoft G., Andreassen T.T., and Oxlund H. Growth hormone can reverse glucocorticoid-induced low bone turnover on cortical but not on cancellous bone surfaces in adult Wistar rats. Bone 36 (2005) 123-133
10. Miyakoshi N. Preventive effects of intermittent administration of human parathyroid hormone on steroid-induced osteopenia in rats. J. Orthop. Sci. 1 (1996) 318-328
11. Andreassen T.T., Jørgensen P.H., Flyvbjerg A., Ørskov H., and Oxlund H. Growth hormone stimulates bone formation and strength of cortical bone in aged rats. J. Bone Miner. Res. 10 (1995) 1057-1067
12. Oxlund H., Andersen N.B., Ørtoft G., Ørskov H., and Andreassen T.T. Growth hormone and mild exercise in combination markedly enhance cortical bone formation and strength in old rats. Endocrinology 139 (1998) 1899-1904
13. Ørtoft G., Andreassen T.T., and Oxlund H. Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia. J. Bone Miner. Res. 14 (1999) 710-721
14. Oxlund H., Ejersted C., Andreassen T.T., Tørring O., and Nilsson M.H.L. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif. Tissue Int. 53 (1993) 394-399
15. Oxlund H., Dalstra M., and Andreassen T.T. Statin given per orally to adult rats increases cancellous bone mass and compressive strength. Calcif. Tissue Int. 69 (2001) 299-304
16. Parfitt A.M. Surface specific bone remodeling in health and disease. In: Kleerenkoper M., and Krane S.M. (Eds). Clinical disorders of bone and mineral metabolism (1989), Mary Ann Liebert Inc., New York 7-14
17. Søgaard C.H., Danielsen C.C., Thorling E.B., and Mosekilde L. Long-term exercise of young and adult female rats: effect on femoral neck biomechanical competence and bone structure. J. Bone. Miner. Res. 9 (1994) 409-416
18. Mosekilde L., Thomsen J.S., Orchii P.B., McCarter R.J., Mejia W., and Kalu D. Additive effect of voluntary exercise and growth hormone treatment on bone strength assessed at four skeletal sites in an aged rat model. Bone 24 (1999) 71-80
19. Oxlund B.S., Ørtoft G., Andreassen T.T., and Oxlund H. Low-intensity, high-frequency vibration appears to prevent the decrease in strength of the femur and tibia associated with ovariectomy of adult rats. Bone 32 (2003) 69-77
20. Oxlund H., and Andreassen T.T. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34 (2004) 609-618
21. Sokal R.R., and Rohlf F.J. Biometry (1981), WH Freeman, San Francisco
22. Dalle Carbonare L., Arlot M.E., Chavassieux P.M., Roux J.P., Portero N.R., and Meunier P.J. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 16 (2001) 97-103
23. Pereira R.M., Delany A.M., and Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28 (2001) 484-490
24. Weinstein R.S., Jilka R.L., Parfitt A.M., and Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102 (1998) 274-282
25. Pereira R.C., Delany A.M., and Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30 (2002) 685-691
26. Delany A.M., Durant D., and Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol. Endocrinol. 15 (2001) 1781-1789
27. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4382-4389
28. Rubin J., Biskobing D.M., Jadhav L., Fan D., Nanes M.S., Perkins S., et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 139 (1998) 1006-1012
29. Dempster D.W., Moonga B.S., Stein L.S., Horbert W.R., and Antakly T. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J. Endocrinol. 154 (1997) 397-406
30. Dobnig H., and Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136 (1995) 3632-3638
31. Nishida S., Yamaguchi A., Tanizawa T., Endo N., Mashiba T., Uchiyama Y., et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15 (1994) 717-723
32. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., and Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104 (1999) 439-446
33. Pfeilschifter J., Laukhuf F., Muller-Beckmann B., Blum W.F., Pfister T., and Ziegler R. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J. Clin. Invest. 96 (1995) 767-774
34. Boguslawski G., Hale L.V., Yu X.P., Miles R.R., Onyia J.E., Santerre R.F., et al. Activation of osteocalcin transcription involves interaction of protein kinase A- and protein kinase C-dependent pathways. J. Biol. Chem. 275 (2000) 999-1006
35. Silver J., and Bushinsky D. Harnessing the parathyroids to create stronger bones. Curr. Opin. Nephrol. Hypertens. 13 (2004) 471-476
36. Huang J.C., Sakata T., Pfleger L.L., Bencsik M., Halloran B.P., Bikle D.D., et al. PTH differentially regulates expression of RANKL and OPG. J. Bone Miner. Res. 19 (2004) 235-244